Health & Fitness
Health and Fitness
Health and Fitness
Mon, June 7, 2010
Sun, June 6, 2010
Sat, June 5, 2010
Fri, June 4, 2010 CytRx to Present at the Jefferies 2010 Global Life Sciences Conference
LOS ANGELES--([ BUSINESS WIRE ])--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that David J. Haen, CytRxa™s Vice President of Business Development, will present at the Jefferies 2010 Global Life Sciences Conference on Friday, June 11, 2010, at 12:45 p.m. Eastern time (9:45 a.m. Pacific time) in New York City.
The CytRx presentation will include a discussion of the Companya™s actions to advance the clinical development of its high-value oncology development pipeline, including a discussion of its recently initiated Phase 2 clinical trial to evaluate the efficacy and safety of bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia, and plans to initiate up to five additional Phase 2 oncology clinical trials in 2010. A live webcast of the presentation will be available at [ www.cytrx.com ] and a webcast replay will be archived on the Companya™s Web site for 90 days.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development oncology company engaged in the development of high-value human therapeutics. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, bafetinib and tamibarotene. The Company recently announced initiation of a Phase 2 clinical trial with bafetinib as a treatment for high-risk B-cell chronic lymphocytic leukemia, and plans to initiate two additional Phase 2 clinical trials in glioblastoma multiforme (a common and aggressive type of primary brain tumor) and advanced prostate cancer. CytRx also recently announced plans to initiate three Phase 2 clinical trials with its oncology candidate INNO-206 as a treatment for pancreatic cancer, gastric cancer and soft tissue sarcomas. In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit [ http://www.cytrx.com ].
